Overview

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to evaluate the non-inferiority of BF-200 ALA (Ameluz) in the treatment of actinic keratosis (AK) with photodynamic therapy (PDT) compared to Metvix.
Phase:
Phase 3
Details
Lead Sponsor:
Biofrontera Bioscience GmbH
Collaborator:
Accovion GmbH
Treatments:
Aminolevulinic Acid
Methyl 5-aminolevulinate